SCHEMBL2192874

SCHEMBL2192874

COc1ccc(Cn2ccn(C)c2=[Pt])cc1OC.IN(I)C1CCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.44
MAPK1 P28482 1/20 0.43
KDM4E B2RXH2 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
MAPT P10636 2/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
ALDH1A1 P00352 6/20 0.38
LMNA P02545 2/20 0.38
HSD17B10 Q99714 2/20 0.38
PDE4B Q07343 1/20 0.37
KMT2A Q03164 3/20 0.37
GAA P10253 1/20 0.36
THRB P10828 1/20 0.36
USP2 O75604 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MEN1 O00255 1/20 0.36
APOBEC3A P31941 1/20 0.36
HTT P42858 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2192469 0.99 SIGMAR1 (0.43) SIGMAR1MAPK1KDM4ESMN1; SMN2MAPT
SCHEMBL2194519 0.99 SIGMAR1 (0.43) SIGMAR1MAPK1KDM4ESMN1; SMN2MAPT
SCHEMBL2192101 0.99 SIGMAR1 (0.45) SIGMAR1MAPK1KDM4ESMN1; SMN2MAPT
SCHEMBL2195084 0.96 SIGMAR1 (0.46) SIGMAR1MAPK1KDM4ESMN1; SMN2MAPT
SCHEMBL2196792 0.85 MAPT (0.40) SIGMAR1MAPTALDH1A1LMNAGAA
SCHEMBL2194325 0.83 LPO (0.52) SIGMAR1MAPK1KDM4EMAPTALDH1A1
SCHEMBL2197185 0.82 SIGMAR1 (0.42) SIGMAR1MAPK1KDM4ESMN1; SMN2MAPT
SCHEMBL2195709 0.81 MAPT (0.41) SIGMAR1KDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL2196582 0.80 CNR1 (0.36) SIGMAR1KDM4EALDH1A1HSD17B10USP2
SCHEMBL2197695 0.79 LPO (0.55) SIGMAR1MAPK1KDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 SIGMAR1 259/4885MAPK1 3174/4885KDM4E 4803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.